468 related articles for article (PubMed ID: 26888382)
21. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
22. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
[TBL] [Abstract][Full Text] [Related]
23. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
24. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
25. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
Pradhan R; Lu S; Yin H; Yu OHY; Ernst P; Suissa S; Azoulay L
BMJ; 2022 Nov; 379():e071380. PubMed ID: 36318979
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
[TBL] [Abstract][Full Text] [Related]
27. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
[TBL] [Abstract][Full Text] [Related]
28. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
[TBL] [Abstract][Full Text] [Related]
29. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
32. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
33. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
[TBL] [Abstract][Full Text] [Related]
34. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
[TBL] [Abstract][Full Text] [Related]
36. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.
Boniol M; Franchi M; Bota M; Leclercq A; Guillaume J; van Damme N; Corrao G; Autier P; Boyle P
Diabetes Care; 2018 Feb; 41(2):286-292. PubMed ID: 29146599
[TBL] [Abstract][Full Text] [Related]
37. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
38. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
39. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
40. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
Lu S; Yin H; Yu OHY; Azoulay L
Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]